Aldagen Issued Key Stem Cell Patent; Patent Covers Unique Method of Isolating Adult Stem Cells
Posted on: Wednesday, 8 February 2006, 09:01 CST
Aldagen, Inc., a company focused on regenerative medicine to treat cardiovascular disease and other degenerative diseases, has been issued U.S. Patent 6,991,897 entitled "A Method of Isolating Stem Cells." The claims of this issued patent describe methods of isolating adult stems from various sources - including human bone marrow, peripheral blood and cord blood - based on the elevated expression of an intracellular enzyme, aldehyde dehydrogenase (ALDH), as a key stem cell marker. This patent complements other issued Aldagen patents with claims protecting the proprietary chemistry in Aldagen's products and kits used to detect, count, and isolate adult stem cells.
"The issuance of this patent further strengthens our intellectual property around Aldagen's unique method for isolating adult stem cells. We have already incorporated this technology into marketed products and are now testing therapeutic applications of our ALDESORT product in human clinical trials. ALDESORT is the only product that yields a mixture of highly active stem cell types from human bone marrow without altering their activities. We have begun an aggressive program of clinical studies to demonstrate the activity of these cell populations in different tissue repair indications," added Ed Field, President and CEO of Aldagen.
About Aldagen, Inc.
Aldagen's proprietary products identify and isolate unique populations of adult stem cells with the potential to revolutionize treatments of cardiovascular and other degenerative diseases. The Company is now testing its therapeutic products in clinical trials. To learn more about Aldagen's products for preparing optimal cell populations for adult stem cell therapy, the Company invites you to visit its website at www.aldagen.com.
Source: Business Wire
Related Articles
- Researchers Advance Understanding Of Stem Cells
- Aldagen's Adult Stem Cell Populations Shown to Regenerate Vascular Function and Repair Liver Damage
- Interim Results of Clinical Study Using Aldagen's Product to Isolate Stem Cells From Cord Blood Presented at American Society of Hematology
- Geron Presents New Data That Document Progress in Development of Therapeutic Products From Human Embryonic Stem Cells
- Geron Announces Issuance of U.S. Patent for Production of Insulin Secreting Cells From Human Embryonic Stem Cells
- Aldagen IND for Stem Cell Clinical Trial to Treat Critical Limb Ischemia Is Cleared By FDA
- Aldagen's Product Used to Isolate Stem Cells From Cord Blood in Human Clinical Study
- StemCells, Inc. Receives FDA Clearance to Initiate Phase I Clinical Trial of Neural Stem Cells to Treat Batten Disease; First-Ever FDA-Approved Trial to Transplant Human Neural Stem Cells
- Chemicon International, Inc. Enters into a License to Commercialize Research Products Utilizing Human Embryonic Stem Cell Technology From Wisconsin Alumni Research Foundation (WARF)
- Japanese scientists grow stem cells into sperm cells
 |
 |
User Comments (0)
RSS Feeds